RCT Licensing Michigan Pioneer Gene Transfer Technology.
TUCSON, Ariz.--(BW HealthWire)--March 8, 2000
Research Corp. Technologies (RCT) is offering nonexclusive licenses to a gene transfer system that has become a biotechnology industry standard.
Flexible licensing terms make this valuable genetic tool patented by the University of Michigan in Ann Arbor available to companies of all sizes and in a variety of disciplines.
Michigan received U.S. Patent No. 5,672,344 in September 1997 for a viral-mediated gene transfer system that uses DNA viruses to introduce new genes into mammalian cells.
Although many other techniques are in use today for introducing genes into cells, researchers Drs. William N. Kelley, Thomas Palella and Myron Levine were the first to propose use of viral DNA vectors as a general way to transfer genes into mammalian cells while working together at Michigan.
They were also the first to directly administer a human gene in vivo and obtain expression in an experimental animal. Their viral-mediated gene transfer system is now a basic technique many companies have adopted over the past decade.
The 1997 patent is based on a parent application Michigan originally filed in 1987. Also, a U.S. patent application is pending with broad claims to viral-based vectors and gene therapy uses.
RCT and Michigan recently signed an agreement assigning the patent and its licensing to RCT. Licensing fees and royalties are based on three fields of use: human gene therapy and DNA vaccines; use in transgenic animals; and general research uses and recombinant protein production.
RCT is also responsible for licensing the technology to companies currently using viral-mediated gene transfer systems.
The viral-mediated gene transfer system is the most recent addition to RCT's growing number of systems and components for gene expression that are available for nonexclusive licensing.
The company's Gene Expression Technologies portfolio includes the Pichia Yeast Protein Expression System, the InsectSelect(TM) Insect Cell Expression System, the bovine growth hormone polyadenylation signal sequence and other promoters and enhancers.
Previously, QED Technologies (http://www.qedtech.com) managed licensing of the gene transfer system for Michigan. The Malvern, Penn., consulting group provides advice and counsel to pharmaceutical, biotechnology, chemical, diagnostic and medical device firms; universities and independent research centers; and investment groups and funds.
For licensing information, contact: Bennett N. Cohen, Ph.D., Director, Commercialization, 520/748-4400, 520/748-0025 fax, E-mail: firstname.lastname@example.org.
RCT (http://www.rctech.com) is an independent technology management company that commercializes technologies from universities and research institutions worldwide. Commercialization vehicles include licensing, partnerships, seed investments and venture development of early-stage technologies.